Eicosapentaenoic acid - SLA Pharma

Drug Profile

Eicosapentaenoic acid - SLA Pharma

Alternative Names: ALFA; EPA-FFA - SLA Pharma; EPA-FFA gastro-resistant capsules - SLA Pharma

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SLA Pharma
  • Developer SLA Pharma; University of Bologna
  • Class Antihyperlipidaemics; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Arachidonic acid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Familial adenomatous polyposis
  • Phase I/II Colorectal cancer; Ulcerative colitis
  • No development reported Crohn's disease; Intestinal polyps

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Crohn's-disease in Italy (PO, Capsule)
  • 17 Jun 2015 Clinical development for Familial adenomatous polyposis is ongoing in the United Kingdom
  • 17 Jun 2015 No recent reports of development identified - Phase-II for Colorectal cancer (Late-stage disease, Metastatic disease, Neoadjuvant therapy) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top